Sjogren's disease and diet

What the research found.

• In 104 people randomized to omega-3 or placebo for two months, dry eye symptoms fell from 10.44 to 4.85 on an 18-point scale. The placebo group fell to 8.27, at a P value of 0.001. Participants, care providers, and investigators were all blinded, which is what separates this trial from everything else written about diet here.

  Al-Rawi and colleagues, Mediterranean Journal of Rheumatology, 2025

• In that same trial the Schirmer tear test improved from 2.38 to 6.63 mm in the omega-3 group. It improved from 2.68 to 5.58 mm on placebo. So the objective measurement improved substantially in both groups, and that's the part most summaries of this trial leave out.

  Al-Rawi and colleagues, Mediterranean Journal of Rheumatology, 2025

• In 114 patients, adherence to a Mediterranean way of eating correlated inversely with the ocular surface disease index, at rho of negative 0.73. The mean index was 13 in good adherence against 33 in poor or moderate adherence. That's a cross-sectional correlation rather than a trial result, so it can't tell you which way the arrow points.

  Chaaya and colleagues, Medical Sciences, 2025

One trial, and what it found

The only properly blinded, placebo-controlled nutrition trial of reasonable size in Sjogren's disease randomized 104 people to omega-3 or placebo for two months. Participants, care providers, and investigators were all blinded, and randomization was web-based. That design is what separates this study from everything else written about diet in this condition.

Dry eye symptoms fell from 10.44 to 4.85 on an 18-point scale in the omega-3 group, against 8.27 on placebo, with a P value of 0.001. The xerostomia inventory score, which measures dry mouth, fell from 2.83 to 1.91 against 2.35 on placebo, at a P value of 0.017. Individual eye symptoms including itching, mucous discharge, and light sensitivity all favored the supplement.

Those are real results and they deserve to be reported as such. Symptoms improved more on omega-3 than on placebo, in a blinded trial, with a hundred participants. In a field this thin, that is notable.

The part of that trial that rarely gets quoted

The objective measurements tell a more complicated story than the symptom scores. The Schirmer test, which measures tear production directly, rose from 2.38 to 6.63 millimetres in the omega-3 group and from 2.68 to 5.58 millimetres in the placebo group. Both improved substantially, and the placebo improvement was significant in its own right at a P value of 0.01.

Saliva production followed the same form. It rose from 0.99 to 2.07 milliliters per 15 minutes on omega-3 and from 1.00 to 1.55 on placebo, and the omega-3 result came out at a P value of 0.053, which doesn't clear the conventional threshold. So the supplement's advantage appears in how people felt rather than in how much they produced.

That distinction is worth taking into any decision about this. Feeling less dry is a legitimate goal and it's what most people want from treatment. It's also a different claim from restoring gland function, and the trial supports the first considerably better than the second.

Everything else is smaller than it sounds

This site holds no other nutrition trial in Sjogren's disease of any size. So the omega-3 trial above is the whole of the good evidence here. The rest of what gets written about dietary management may alleviate sicca symptoms and improve nutritional status while current evidence is insufficient to support specific recommendations. That's the whole field summarizing itself.

The individual findings inside it show why. A liquid diet raised unstimulated salivary flow from 1.18 to 1.70 milliliters per 15 minutes over four weeks. Twelve months of vitamins with evening primrose oil improved tear and saliva production in five people. A plant-based diet improved dry mouth and dry eyes in three patients over four weeks, and a gluten-free diet over two months improved tear secretion with dry mouth unchanged.

Those are studies of three people and five people, with no control groups at all. They're observations that justify running a trial rather than results from one, and treating them as evidence of efficacy is just how confident advice gets built on nothing. The review also covered animal work suggesting low-fat feeding, caloric restriction, and fasting reduce glandular infiltration, which is interesting and isn't evidence about people.

The Mediterranean correlation, and why it points both ways

A cross-sectional study of 114 patients found adherence to a Mediterranean way of eating correlated inversely with the ocular surface disease index, at rho of negative 0.73. The mean index was 13 in those with good adherence against 33 in those with poor or moderate adherence, and the correlation held at both shorter and longer disease duration. Fatty acid intake correlated with the same index at negative 0.67.

That's a strong correlation and it comes from a single moment in time. Diet and dryness were measured together, so the study can't tell you whether eating this way reduces dryness or whether people whose symptoms are milder find it easier to shop, cook, and eat well. Severe dry mouth makes eating a chore, and a chore is where varied cooking goes first.

The finding is worth having and worth reading as a reason to run a trial. Presenting it as evidence that a way of eating treats ocular dryness goes past what a cross-sectional design can support, however large the correlation. No study that measures everything at one moment can settle the order things happened in.

What's practical while the evidence catches up

Dry mouth changes the dental calculation more than most people realize. Saliva is a protection against decay that goes unnoticed until it's gone, which makes how often you eat sugar more important than how much, and makes regular dental care more valuable here than for other people. Telling your dentist you have Sjogren's disease changes what they look for.

Restriction deserves more caution in this condition than in most. Dryness already makes eating harder, chewing and swallowing take longer, and removing food groups on top of that puts nutritional adequacy at real risk rather than theoretical risk. Any elimination worth trying is worth doing with supervision and with an end date.

The last practical point comes from the trial itself. The placebo group improved on the objective tear measurement, which means anyone starting something new should expect a period of feeling better that may have nothing to do with what they started. Planning to reassess at two or three months, rather than at two or three weeks, is what gives you a chance of telling the difference.

Common misconceptions.

Cautions specific to this condition.

• Both the blood test and the biopsy for celiac disease lose accuracy once gluten is already out of the diet. So the order those happen in changes what the result is worth.
• Tell your rheumatology team about supplements, since omega-3 at supplement doses affects bleeding and interacts with anticoagulants.
• Treat dry mouth as a dental problem as well as a comfort one, because reduced saliva raises the risk of decay and that risk changes what's sensible about sugar.
• Be careful with prolonged restriction, since dryness already makes eating harder and cutting food groups on top of it puts nutritional adequacy at risk.
• Expect a placebo response and plan around it, because the placebo group in the one good trial improved on the objective tear measurement too.
• Ask about any product marketed for Sjogren's specifically, because the whole human evidence base in this condition is 10 studies.

Questions patients ask.